Prognosis
Glaxo Aims for HIV Cure by 2030 as It Looks to Post-Split Future
This article is for subscribers only.
GlaxoSmithKline Plc told investors it’s aiming to develop a cure for HIV by 2030, as the company outlines its future ahead of splitting in two next year.
“Our ultimate goal is always a cure of HIV,” Kimberly Smith, head of research and development at Glaxo’s HIV arm ViiV Healthcare, told investors in a presentation on the business Monday. I hope “that we’ll contribute to getting there by 2030 if not sooner.”